Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CLZNY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CLZNY and 80,000+ other tickers.
See exactly how CLZNY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CLZNY and 80,000+ other tickers.
Clariant AG engages in the development, manufacture, distribution, and sale of specialty chemicals. It operates through the following segments: Care Chemicals, Catalysis, Natural Resources, and Corporate. The Care Chemicals segment is composed of industrial and consumer specialties with a focus on applications and formulations for personal care, home care, crop solutions, paints and coatings, aviation, construction chemicals, and industrial lubricants. The Catalysis segment develops, manufactures, and sells catalyst products for the chemical, fuel, and automotive industries. The Natural…
Shares of Clariant AG (OTCMKTS:CLZNY - Get Free Report) have been assigned an average rating of "Hold" from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, three have given a buy recommendation and one
Clariant AG (CLZNY) Q2 2026 Earnings Call Transcript
Clariant AG (CLZNY) Q1 2026 Earnings Call Transcript
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR FIRST QUARTER | 2026 Q1 2026 sales decreased by 2 % in local currencies 1 to CHF 918 million with the Middle East conflict impacting Catalyst volumes and portfolio pruning affecting Care Chemicals; 0.5 % decline excluding portfolio pruning Q1 2026 EBITDA margin before exceptional items of 17.5 % decreased by 130 basis points compared to a strong Q1 2025 mainly due to the Middle East conflict and a one-off impacting Catalysts Q1 2026 free cash flow conversion improved by 12 percentage points to 54 % (LTM basis), achieved through effective net working capital management and continued disciplined Capex On track to achieve the remaining CHF 30 million of the total CHF 80 million performance improvement program savings (Investor Day 2024) already in 2026, with CHF 9 million achieved in the first quarter Guidance 2026 remains unchanged while Middle East conflict particularly impacting demand in our Catalysts business, causing increasing input costs, and overall elevated uncertainty and volatility “In the first quarter of 2026, Clariant delivered flat underlying sales, excluding the effects of our proactive portfolio pruning measures.
Clariant has released its Integrated Report 2025, which provides a comprehensive overview of both the company's financial and non-financial performance